Demographic | | | | | | | |
Age, median (IQR) | 295 | 61.0 (50.0–68.0) | 152 | 59.0 (49.0–66.0) | 143 | 63.0 (52.0–69.0) | 0.031 |
Male, n (%) | 296 | 163 (55.1) | 152 | 88 (57.9) | 144 | 75 (52.1) | 0.315 |
White ethnicity, n (%) | 294 | 293 (99.7) | 150 | 149 (99.3) | 144 | 144 (100.0) | 1.000 |
|
Highest educational qualification attained | 294 | | 152 | | 143 | | 0.582 |
No qualification, n (%) | | 16 (5.4) | | 10 (6.6) | | 6 (4.2) | |
O-Level or GCSE, n (%) | | 22 (7.5) | | 10 (6.6) | | 12 (8.4) | |
A-Level, n (%) | | 13 (4.4) | | 8 (5.3) | | 5 (3.5) | |
Professional qualification, n (%) | | 91 (31.0) | | 42 (27.8) | | 49 (34.3) | |
University degree, n (%) | | 152 (51.7) | | 81 (53.6) | | 71 (49.7) | |
|
Condition requiring anticoagulation | 296 | | 152 | | 144 | | 0.403 |
Antiphospholipid syndrome, n (%) | | 25 (8.4) | | 13 (8.6) | | 12 (8.3) | |
Atrial fibrillation, n (%) | | 68 (23.0) | | 40 (26.3) | | 28 (19.4) | |
Mechanical heart valve, n (%) | | 97 (32.8) | | 44 (28.9) | | 53 (36.8) | |
Thrombosis, n (%) | | 106 (35.8) | | 55 (36.2) | | 51 (35.4) | |
|
Oral anticoagulation history | | | | | | | |
Target INR, median (IQR) | 296 | 2.5 (2.5–3.2) | 152 | 2.5 (2.5–3.0) | 144 | 3.0 (2.5–3.3) | 0.088 |
Duration of OAT, months, median (IQR) | 295 | 62.0 (14.0–137.0) | 151 | 21.0 (7.0–74.0) | 144 | 107.0 (56.3–162.5) | <0.001 |
Previous OAT complication, n (%) | 295 | 101 (34.2) | 152 | 48 (31.6) | 143 | 53 (37.1) | 0.321 |
Taking OAT other than warfarin, n (%) | 296 | 10 (3.4) | 152 | 4 (2.6) | 144 | 6 (4.2) | 0.469 |
|
Characteristics of self-monitoring | | | | | | | |
Duration, months, median (IQR) | 295 | 2.0 (1.0–65.0) | 151 | 1.0 (0.0–1.0) | 144 | 65.0 (8.8–94.5) | <0.001 |
Received in-person self-monitoring training, n (%) | 296 | 136 (45.9) | 152 | 69 (45.4) | 144 | 67 (46.5) | 0.845 |
Duration of in-person training for those that received it in minutes, median (IQR) | 129 | 35.0 (20.0–60.0) | 66 | 30.0 (20.0–60.0) | 63 | 45.0 (20.0–80.0) | 0.010 |
|
Other medications | | | | | | | |
Total medications, median (IQR) | 296 | 3.0 (1.0–5.0) | 152 | 3.0 (1.0–5.0) | 144 | 3.0 (1.0–6.0) | 0.213 |
Polypharmacy (total >3), n (%) | 296 | 129 (43.6) | 152 | 62 (40.8) | 144 | 67 (46.5) | 0.320 |
Taking medication that affects anticoagulation, n (%) | 296 | 167 (56.4) | 152 | 83 (54.6) | 144 | 84 (58.3) | 0.580 |
|
Oral anticoagulation dose management | 296 | | 152 | | 144 | | <0.001 |
Self-testing, n (%) | | 133 (44.9) | | 79 (52.0) | | 54 (37.5) | |
Mixed, n (%) | | 47 (15.9) | | 34 (22.4) | | 13 (9.0) | |
Self-managing, n (%) | | 116 (39.2) | | 39 (25.7) | | 77 (53.5) | |